Onishi Tetsuro, Suzuki Hiroyoshi, Igarashi Tatsuo
The Department of Urology, Seirei Citizen Hospital.
Hinyokika Kiyo. 2012 Jan;58(1):25-9.
We present a patient showing favourable response after combination treatment with interferon-α (IFN- α) and cyclooxygenase-2 (Cox-2) inhibitor (celecoxib) against metastatic renal cell carcinoma (RCC). The patient underwent left radical nephrectomy for RCC on 18th April, 2005. On follow-up computed tomographic scan, mediastinal metastasis was detected 3 years after nephrectomy, and metastasectomy was performed. The histological features were clear cell carcinoma as was the primary RCC, and immunohistochemical analysis revealed negative for Cox-2 staining both the primary and metastatic lesions. Aiming at the treatment of residual mediastinal RCC, the patient started to receive IFN-α, and this cytokine therapy lasted for 1 year and 2 months. Nevertheless, the outcome was progression of disease (PD), namely, new lung field lesions were observed. A different type of IFN-α treatment also resulted in PD. Based upon these results, a combination of IFN-α and Cox-2 inhibitor was newly adopted for treatment. After the combination therapy for 3 months, 68.75% of metastases disappeared. We concluded that Cox-2 inhibitor is a potent medicine in combination with IFN-α for metastatic lung tumour from RCC.
我们报告了一名转移性肾细胞癌（RCC）患者，其在接受α干扰素（IFN-α）和环氧合酶-2（Cox-2）抑制剂（塞来昔布）联合治疗后出现了良好反应。该患者于2005年4月18日因RCC接受了左肾根治性切除术。在随访计算机断层扫描中，肾切除术后3年检测到纵隔转移，并进行了转移灶切除术。组织学特征为透明细胞癌，与原发性RCC相同，免疫组化分析显示原发性和转移性病变的Cox-2染色均为阴性。为了治疗残留的纵隔RCC，患者开始接受IFN-α治疗，这种细胞因子治疗持续了1年零2个月。然而，结果是疾病进展（PD），即观察到新的肺野病变。另一种类型的IFN-α治疗也导致了PD。基于这些结果，新采用了IFN-α和Cox-2抑制剂联合治疗。联合治疗3个月后，68.75%的转移灶消失。我们得出结论，Cox-2抑制剂与IFN-α联合使用对RCC转移性肺肿瘤是一种有效的药物。
